The immunosuppressant rapamycin, alone or with transforming growth factor-β, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand

被引:49
作者
Shui, C [1 ]
Riggs, BL [1 ]
Khosla, S [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Endocrinol & Metab, Endocrine Res Unit, Rochester, MN 55905 USA
关键词
immunosuppressant; osteoclast; transforming growth factor beta; RANK-ligand;
D O I
10.1007/s00223-001-1138-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunosuppressant therapy is known to cause bone loss. Since this may partly result from direct effects on osteoclast development, we investigated whether cyclosporin A (CsA), rapamycin, or FK506 affect osteoclastic differentiation of RAW264.7 monocytic cells induced by RANK-ligand (RANKL). Furthermore, since the rapamycin receptor protein binds transforming growth factor beta (TGF-beta) receptors, and TGF-beta enhances osteoclastogenesis induced by RANKL, we also examined potential synergistic effects of rapamycin and TGF-beta(1). Rapamycin inhibited cell proliferation and stimulated tartrate-resistant acid phosphatase (TRAP) activity of RAW cells in a dose-dependent manner. At the optimal concentration of 10 ng/ml, it increased the number of TRAP(+) multinucleated cells (MNC) more than 20-fold and enhanced the expression of TRAP and calcitonin receptor (CTR) mRNAs 2.1- and 10-fold, respectively. CsA, at 125-2000 ng/ml, similarly inhibited proliferation, but at high doses (1000-2000 ng/ml) it decreased TRAP activity, TRAP(+)MNC formation, and the expression of TRAP and CTR mRNAs. FK506 had no effect on cell proliferation or TRAP activity at concentrations up to 2000 ng/ml; however, like CsA, 1000 ng/ml FK506 inhibited TRAP+MNC formation and the expression of TRAP and CTR mRNAs. The combination of rapamycin (10 ng/ml) and TGF-beta(1) (1 ng/ml) increased TRAP(+)MNC 3.1- and 6.9-fold as compared with rapamycin or TGF-beta(1) alone, respectively, and enhanced CTR mRNA expression induced by TGF-beta(1) by 1.9-fold. Rapamycin also increased osteoclastic resorption activity by 6.5-fold compared with control, and this was enhanced further by the addition of TGF-beta by 3-fold, compared with rapamycin alone. These data thus indicate that rapamycin, alone or in synergy with TGF-beta, directly enhances osteoclastogenesis and may affect bone metabolism in vivo after long-term use.
引用
收藏
页码:437 / 446
页数:10
相关论文
共 65 条
[1]   High turnover bone disease following lung transplantation [J].
Aringer, M ;
Kiener, HP ;
Koeller, MD ;
Artemiou, O ;
Zuckermann, A ;
Wieselthaler, G ;
Klepetko, W ;
Seidl, G ;
Kainberger, F ;
Bernecker, P ;
Smolen, JS ;
Pietschmann, P .
BONE, 1998, 23 (05) :485-488
[2]   Molecular and functional evidence for calcineurin-A α and β isoforms in the osteoclast:: Novel insights into cyclosporin A action on bone resorption [J].
Awumey, EM ;
Moonga, BS ;
Sodam, BR ;
Koval, AP ;
Adebanjo, OA ;
Kumegawa, M ;
Zaidi, M ;
Epstein, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 254 (01) :248-252
[3]  
BERTOLINI DR, 1993, J BONE MINER RES, V8, pS315
[4]   The role of testosterone in cyclosporine-induced osteopenia [J].
Bowman, AR ;
Sass, DA ;
Dissanayake, IR ;
Ma, YF ;
Liang, H ;
Yuan, Z ;
Jee, WSS ;
Epstein, S .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (04) :607-615
[5]   Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002 [J].
Brunn, GJ ;
Williams, J ;
Sabers, C ;
Wiederrecht, G ;
Lawrence, JC ;
Abraham, RT .
EMBO JOURNAL, 1996, 15 (19) :5256-5267
[6]   TRANSFORMING GROWTH-FACTOR-BETA GENE FAMILY MEMBERS AND BONE [J].
CENTRELLA, M ;
HOROWITZ, MC ;
WOZNEY, JM ;
MCCARTHY, TL .
ENDOCRINE REVIEWS, 1994, 15 (01) :27-39
[7]   Mechanism of TGF beta receptor inhibition by FKBP12 [J].
Chen, YG ;
Liu, F ;
Massague, J .
EMBO JOURNAL, 1997, 16 (13) :3866-3876
[8]  
Cooper D K, 1986, J Heart Transplant, V5, P29
[9]   RAPAMYCIN BUT NOT FK506 INHIBITS THE PROLIFERATION OF MONONUCLEAR PHAGOCYTES INDUCED BY COLONY-STIMULATING FACTORS [J].
COOPER, MH ;
GREGORY, SH ;
STARZL, TE ;
WING, EJ .
TRANSPLANTATION, 1994, 57 (03) :433-439
[10]  
Crowe A, 1999, DRUG METAB DISPOS, V27, P627